MX2010010471A - Derivado de tetrahidroisoquinolina novedoso. - Google Patents
Derivado de tetrahidroisoquinolina novedoso.Info
- Publication number
- MX2010010471A MX2010010471A MX2010010471A MX2010010471A MX2010010471A MX 2010010471 A MX2010010471 A MX 2010010471A MX 2010010471 A MX2010010471 A MX 2010010471A MX 2010010471 A MX2010010471 A MX 2010010471A MX 2010010471 A MX2010010471 A MX 2010010471A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- formula
- substituted
- substituent
- members
- Prior art date
Links
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- -1 phenylaminocarbonyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 abstract 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000002891 anorexigenic effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto o una sal farmacológicamente aceptable del mismo que tiene un excelente efecto inhibidor de la DGAT y efecto supresor de la alimentación. La presente invención provee un compuesto representado por la fórmula general (I), o sal farmacológicamente aceptable del mismo: (Ver fórmula I) [en donde, R1 representa un grupo fenilaminocarbonilo que puede estar sustituido con 1 a 5 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes, un grupo benzoxazol-2-ilo que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo A de Sustituyentes, o similares; R2 independientemente representa un grupo alquilo de C1-C6 R3 representa un grupo representado por la fórmula -C(=O)-O-R4 o similar; R4 representa un átomo de hidrógeno, un grupo alquilo de C1,-C6 que puede estar sustituido con 1 a 3 grupo(s) independientemente seleccionados del Grupo B de Sustituyentes, o similares; X representa un átomo de oxígeno, un grupo metileno, o un grupo representado por la fórmula -NH-, o similares; L representa un enlace simple, un grupo metileno, o similares;...... representa un enlace simple o un enlace doble; m representa 1 o 2; n representa un entero de 0 a 5; El Grupo A de Sustituyentes representa un átomo de halógeno, un grupo alquilo de C1-C6, un grupo alquilo de C1-C6 halogenado, un grupo alcoxi de C1-C6, o similares; y el Grupo B de Sustituyentes representa un grupo cicloalquilo de C3-C6, un grupo fenilo, un grupo carboxilo, o similares].
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008079901 | 2008-03-26 | ||
| PCT/JP2009/055738 WO2009119534A1 (ja) | 2008-03-26 | 2009-03-24 | 新規テトラヒドロイソキノリン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010010471A true MX2010010471A (es) | 2010-10-20 |
Family
ID=41113726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010010471A MX2010010471A (es) | 2008-03-26 | 2009-03-24 | Derivado de tetrahidroisoquinolina novedoso. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8735425B2 (es) |
| EP (1) | EP2256105B1 (es) |
| JP (2) | JP4531127B2 (es) |
| KR (1) | KR20100124771A (es) |
| CN (1) | CN101981012A (es) |
| AU (1) | AU2009230127B2 (es) |
| BR (1) | BRPI0913986A2 (es) |
| CA (1) | CA2719721C (es) |
| CO (1) | CO6251285A2 (es) |
| IL (1) | IL208168A (es) |
| MX (1) | MX2010010471A (es) |
| MY (1) | MY161992A (es) |
| NZ (1) | NZ587630A (es) |
| RU (1) | RU2474575C2 (es) |
| TW (1) | TW200944505A (es) |
| WO (1) | WO2009119534A1 (es) |
| ZA (1) | ZA201006563B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101415683B (zh) | 2006-03-31 | 2013-07-17 | 诺瓦提斯公司 | 新化合物 |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| WO2009119534A1 (ja) * | 2008-03-26 | 2009-10-01 | 第一三共株式会社 | 新規テトラヒドロイソキノリン誘導体 |
| AU2009288399B2 (en) | 2008-08-25 | 2013-03-07 | Novartis Ag | Hedgehog pathway modulators |
| IN2012DN01203A (es) * | 2009-08-28 | 2015-04-10 | Daiichi Sankyo Co Ltd | |
| CN102834099B (zh) * | 2010-03-30 | 2015-05-27 | 诺华有限公司 | Dgat1抑制剂的用途 |
| FR2963005B1 (fr) * | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1077173A (en) | 1965-03-19 | 1967-07-26 | American Cyanamid Co | Substituted alkylene piperidines and methods of preparation thereof |
| NL7800026A (nl) | 1977-01-07 | 1978-07-11 | Acna | Werkwijze voor de bereiding van gesubstitueerde amino-benzenen. |
| GB8609630D0 (en) | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
| US20010009912A1 (en) | 1995-02-10 | 2001-07-26 | Christos Tsaklakidis | New derivatives of pyridil piperazine or pyridazinyl piperazyl, process for production thereof and medicaments containing these compounds |
| DZ2769A1 (fr) | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| JP2000026294A (ja) | 1998-05-07 | 2000-01-25 | Sankyo Co Ltd | アリ―ルウレア又はアリ―ルメチルカルバモイル誘導体を含有する医薬 |
| GB0028483D0 (en) * | 2000-11-22 | 2001-01-10 | Hoffmann La Roche | Hydroxyethylamine HIV protease inhibitors |
| MXPA01012317A (es) | 2000-12-28 | 2002-07-22 | Warner Lambert Co | Prueba de aciltransferasa del diacilglicerol (dgat). |
| US20020127626A1 (en) * | 2001-01-05 | 2002-09-12 | Sensors For Medicine And Science, Inc. | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| CA2468184A1 (fr) | 2001-11-28 | 2003-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R A.S.) | Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicament |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| JP4231999B2 (ja) | 2002-12-19 | 2009-03-04 | ダイキン工業株式会社 | ω−ヨウ化含フッ素アルキルビニルエーテルの製造方法 |
| US7328301B2 (en) * | 2003-04-07 | 2008-02-05 | Intel Corporation | Dynamically mapping block-alterable memories |
| AU2004259717A1 (en) * | 2003-07-22 | 2005-02-03 | Merck & Co., Inc. | Piperidine derivatives as melanocortin-4 receptor agonists |
| US7605161B2 (en) | 2003-07-30 | 2009-10-20 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
| WO2005072740A2 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
| ATE400567T1 (de) | 2004-06-23 | 2008-07-15 | Lilly Co Eli | Kinaseinhibitoren |
| JP2006045209A (ja) | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006004200A1 (ja) * | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| ES2343812T3 (es) | 2004-12-03 | 2010-08-10 | F. Hoffmann-La Roche Ag | Derivados de piperidina 3-sustituidos como antagonistas del receptor h3. |
| JPWO2006095922A1 (ja) * | 2005-03-10 | 2008-08-21 | 京都薬品工業株式会社 | テトラヒドロイソキノリン化合物およびその医薬用途 |
| JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
| JP2007191471A (ja) * | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
| WO2007074753A1 (ja) | 2005-12-27 | 2007-07-05 | Daiichi Sankyo Company, Limited | 置換されたウレア誘導体を含有する医薬 |
| EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
| WO2009119534A1 (ja) * | 2008-03-26 | 2009-10-01 | 第一三共株式会社 | 新規テトラヒドロイソキノリン誘導体 |
-
2009
- 2009-03-24 WO PCT/JP2009/055738 patent/WO2009119534A1/ja active Application Filing
- 2009-03-24 BR BRPI0913986A patent/BRPI0913986A2/pt not_active IP Right Cessation
- 2009-03-24 KR KR1020107020729A patent/KR20100124771A/ko not_active Withdrawn
- 2009-03-24 AU AU2009230127A patent/AU2009230127B2/en not_active Ceased
- 2009-03-24 MY MYPI2010004025A patent/MY161992A/en unknown
- 2009-03-24 MX MX2010010471A patent/MX2010010471A/es active IP Right Grant
- 2009-03-24 CA CA2719721A patent/CA2719721C/en not_active Expired - Fee Related
- 2009-03-24 JP JP2010505647A patent/JP4531127B2/ja not_active Expired - Fee Related
- 2009-03-24 CN CN2009801125321A patent/CN101981012A/zh active Pending
- 2009-03-24 EP EP09725300.9A patent/EP2256105B1/en not_active Not-in-force
- 2009-03-24 RU RU2010143586/04A patent/RU2474575C2/ru not_active IP Right Cessation
- 2009-03-24 NZ NZ587630A patent/NZ587630A/en not_active IP Right Cessation
- 2009-03-25 TW TW098109649A patent/TW200944505A/zh unknown
-
2010
- 2010-05-13 JP JP2010110895A patent/JP2010215640A/ja active Pending
- 2010-09-09 US US12/878,170 patent/US8735425B2/en not_active Expired - Fee Related
- 2010-09-13 ZA ZA2010/06563A patent/ZA201006563B/en unknown
- 2010-09-15 IL IL208168A patent/IL208168A/en not_active IP Right Cessation
- 2010-10-22 CO CO10131510A patent/CO6251285A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL208168A0 (en) | 2010-12-30 |
| BRPI0913986A2 (pt) | 2015-10-20 |
| US8735425B2 (en) | 2014-05-27 |
| ZA201006563B (en) | 2011-10-26 |
| CA2719721C (en) | 2012-12-18 |
| CO6251285A2 (es) | 2011-02-21 |
| EP2256105B1 (en) | 2013-12-04 |
| TW200944505A (en) | 2009-11-01 |
| EP2256105A4 (en) | 2011-09-14 |
| KR20100124771A (ko) | 2010-11-29 |
| RU2010143586A (ru) | 2012-05-10 |
| US20110034481A1 (en) | 2011-02-10 |
| JPWO2009119534A1 (ja) | 2011-07-21 |
| IL208168A (en) | 2013-04-30 |
| JP4531127B2 (ja) | 2010-08-25 |
| JP2010215640A (ja) | 2010-09-30 |
| CA2719721A1 (en) | 2009-10-01 |
| AU2009230127B2 (en) | 2011-12-22 |
| WO2009119534A1 (ja) | 2009-10-01 |
| NZ587630A (en) | 2011-07-29 |
| RU2474575C2 (ru) | 2013-02-10 |
| CN101981012A (zh) | 2011-02-23 |
| EP2256105A1 (en) | 2010-12-01 |
| AU2009230127A1 (en) | 2009-10-01 |
| MY161992A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200745034A (en) | New compounds | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| WO2008108386A1 (ja) | 医薬組成物 | |
| TW200730514A (en) | Morpholine type cinnamide compound | |
| TN2010000091A1 (en) | Substituted pyrazole derivative | |
| TW200606137A (en) | Urea derivatives | |
| MX2009010024A (es) | Nuevo compuesto de adenina. | |
| TW200642683A (en) | Heterocyclic compound | |
| WO2008111441A1 (ja) | 医薬組成物 | |
| MX2010010471A (es) | Derivado de tetrahidroisoquinolina novedoso. | |
| MY160443A (en) | Nitrogen-containing heterocyclic compound and agricultural fungicide | |
| PH12012501711A1 (en) | [5,6] heterocyclic compound | |
| UA105185C2 (uk) | Піроли | |
| WO2008078686A1 (ja) | オキシムエステル化合物及び該化合物を含有する光重合開始剤 | |
| MY153910A (en) | BICYCLIC y-AMINO ACID DERIVATIVE | |
| EP1724262A4 (en) | 1- (2H) -ISOCHINOLONDERIVAT | |
| NO20071873L (no) | DNA-PK inhibotorer. | |
| UA107657C2 (uk) | Похідні бензофурану | |
| MY152972A (en) | Azabicyclo compound and salt thereof | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| TW200605883A (en) | Condensed heterocycle derivative having HCV inhibitory activity | |
| MX2010013275A (es) | Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano. | |
| WO2009069736A1 (ja) | 含窒素化合物 | |
| NO20083408L (no) | Korrosjonsinhibitorer som har okt biologisk nedbrytbarhet og redusert giftighet | |
| UA95972C2 (ru) | Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |